In one paragraphArticle in Journal of human immunity, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Laure DelavalSorbonne Université, Inserm, Centre D'Immunologie et des Maladies Infectieuses , Paris, France.ORCID 0000-0002-8340-7193 Karim DorghamSorbonne Université, Inserm, Centre D'Immunologie et des Maladies Infectieuses , Paris, France.ORCID 0000-0001-9539-3203 Jehane FadlallahNational Reference Center for Adult Primary Immunodefiencies, CEREDIH, Hôpital Saint-Louis, Université Paris-Cité , Paris, France.ORCID 0000-0003-3064-9401 Emilie CorvilainNational Reference Center for Adult Primary Immunodefiencies, CEREDIH, Hôpital Saint-Louis, Université Paris-Cité , Paris, France.ORCID 0009-0000-4257-4051 Pierre-Emmanuel RautouUniversité Paris-Cité, Inserm, Centre de Recherche sur L'inflammation, UMR 1149 , Paris, France.ORCID 0000-0001-9567-1859 Eric OksenhendlerNational Reference Center for Adult Primary Immunodefiencies, CEREDIH, Hôpital Saint-Louis, Université Paris-Cité , Paris, France.ORCID 0000-0001-8588-7138 Claire FieschiNational Reference Center for Adult Primary Immunodefiencies, CEREDIH, Hôpital Saint-Louis, Université Paris-Cité , Paris, France.ORCID 0000-0003-2136-6178 Guy GorochovSorbonne Université, Inserm, Centre D'Immunologie et des Maladies Infectieuses , Paris, France.ORCID 0000-0003-2097-9677 Marion MalphettesNational Reference Center for Adult Primary Immunodefiencies, CEREDIH, Hôpital Saint-Louis, Université Paris-Cité , Paris, France.ORCID 0000-0002-9888-2528 Funding
Agence Nationale de la Recherche ANR-18-CE14-0006-01Agence Nationale de la Recherche ANR-18-IDEX-0001Agence Nationale de la Recherche ANR-21-CE17-0037Agence Nationale de la Recherche ANR-21-RHUS-0008Agence Nationale de la Recherche ANR-23-CE17-0020Agence Nationale de la Recherche RHU QUID-NASHÉmergence, Ville de ParisEuropean Innovation Council 101162457European Union 847949Fondation ARCFonds de Dotation CSL Behring pour la RechercheFrench Foundation for Medical Research EQU202203014622French National Reference Center of Primary ImmunodeficienciesInstitut National de la Santé et de la Recherche MédicaleParis Region DIM ITACSorbonne Université
6 · The paper itselfAbstract
Serum soluble CD14 (sCD14) is used as a surrogate marker for bacterial translocation. This cohort study demonstrates that higher baseline sCD14 levels are an independent biomarker for porto-sinusoidal vascular disease risk in patients with common variable immunodeficiency.
What OpenQuestion holds
Textmetadata
Read underepoch 390